Silence Therapeutics plc (SLN) is a Biotechnology company in the Healthcare sector, currently trading at $7.28. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is SLN = $57 (+683% upside).
Valuation: SLN trades at a trailing Price-to-Earnings (P/E) of -3 (S&P 500 average ~25).
Financials: revenue is $559,000, +5.6%/yr average growth. Net income is $89M (loss), growing at -35.7%/yr. Net profit margin is -15851.9% (negative). Gross margin is 61.5% (+23.7 pp trend).
Balance sheet: total debt is -$160,000 against $62M equity (Debt-to-Equity (D/E) ratio -0, conservative). Current ratio is 8.72 (strong liquidity). Debt-to-assets is -0.1%. Total assets: $131M.
Analyst outlook: 4 / 5 analysts rate SLN as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
